慢性髓性白血病：生物学与治疗。
Chronic myeloid leukaemia: Biology and therapy.
机构信息
Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
出版信息
Blood Rev. 2024 May;65:101196. doi: 10.1016/j.blre.2024.101196. Epub 2024 Mar 27.
Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.
慢性髓性白血病（CML）由 BCR::ABL1 引起。酪氨酸激酶抑制剂（TKI）是初始治疗方法。一些组织已经报告了评估对初始 TKI 治疗反应的里程碑，并建议何时应考虑更换 TKI。实现无治疗缓解（TFR）越来越被认为是最佳的治疗目标。哪种 TKI 是哪种人的最佳初始治疗方法，以及需要达到何种分子缓解深度和持续时间才能实现 TFR，这些都是有争议的。在这篇综述中，我们讨论了这些问题，并提出了未来的研究方向。
Zotero 插件